← All trials
NCT04234113
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 13, 2019
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 96
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Accord ResearchLead sponsor
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Anus Neoplasms
- Biliary Tract Neoplasms
- Urinary Bladder Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Uterine Cervical Neoplasms
- Carcinoma, Hepatocellular
- Melanoma
- Mesothelioma
- Ovarian Neoplasms
- Stomach Neoplasms
- Thymus Neoplasms
- Thyroid Gland
- Thyroid Neoplasms
- Carcinoma, Merkel Cell
- Microsatellite Instability
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.